These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2585201)

  • 21. Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.
    Cortesina G; De Stefani A; Galeazzi E; Cavallo GP; Badellino F; Margarino G; Jemma C; Forni G
    Br J Cancer; 1994 Mar; 69(3):572-6. PubMed ID: 8123489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.
    Geertsen PF; Hermann GG; von der Maase H; Steven K
    J Clin Oncol; 1992 May; 10(5):753-9. PubMed ID: 1569448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
    Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
    J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
    Atzpodien J; Körfer A; Evers P; Franks CR; Knüver-Hopf J; Lopez-Hänninen E; Fischer M; Mohr H; Dallmann I; Hadam M
    Mol Biother; 1990 Mar; 2(1):18-26. PubMed ID: 2334534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
    Melioli G; Margarino G; Scala M; Mereu P; Bertoglio S; Schenone G; Barbaresi M; Machí AM; Santi L; Badellino F
    Laryngoscope; 1992 May; 102(5):572-8. PubMed ID: 1533435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
    Bukowski RM
    Cancer; 1997 Oct; 80(7):1198-220. PubMed ID: 9317170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiosarcoma of the scalp treated with OK-432 and rIL-2.
    Miura H; Inui S; Sakai H; Hasebe N; Itami S; Yoshikawa K
    Int J Dermatol; 2002 May; 41(5):286-8. PubMed ID: 12100706
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
    Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
    Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ
    Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases.
    Meloni G; Vignetti M; Andrizzi C; Capria S; Foa R; Mandelli F
    Leuk Lymphoma; 1996 May; 21(5-6):429-35. PubMed ID: 9172807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical application of continuous infusion of recombinant interleukin-2.
    West WH
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
    Stoter G; Shiloni E; Aamdal S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S41-3. PubMed ID: 2697578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Improved therapeutic effect of sequential immunotherapy with cyclophosphamide, large doses of OK-432 and recombinant interleukin-2 in breast cancer patients with disseminated metastatic liver tumors].
    Akimoto M; Nishihira T; Hirakawa H; Abe M; Ohuchi N; Mori S; Kumagai K
    Nihon Geka Gakkai Zasshi; 1991 Jan; 92(1):64-74. PubMed ID: 2014029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors.
    Duvillard C; Romanet P; Cosmidis A; Beaudouin N; Chauffert B
    Ann Otol Rhinol Laryngol; 2004 Mar; 113(3 Pt 1):229-33. PubMed ID: 15053208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma.
    Urba SG; Forastiere AA; Wolf GT; Amrein PC
    Cancer; 1993 Apr; 71(7):2326-31. PubMed ID: 8453554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
    Tamura T; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Fujiwara Y; Nakagawa K; Minato K; Bungo M; Saijo N
    Cancer Res; 1989 Feb; 49(3):730-5. PubMed ID: 2783385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.